Evaluation of efficacy and patient satisfaction with topical heparin gel 2400 IU/g in the treatment of superficial vein thrombophlebitis

Introduction: Superficial vein thrombophlebitis (SVT) is an inflammatory and thrombotic condition of superficial veins, often linked with varicose veins and at risk of progressing to deep vein thrombosis (DVT) or pulmonary embolism (PE). Materials and methods: This study evaluated the efficacy of topical heparin gel (Fortiven Activ Gel, 2400 IU/g, PPF Hasco-Lek S.A., Poland) in treating SVT. Sixty-nine patients used the gel for 14 days according to the Summary of Product Characteristics (SmPC). At the first visit, demographic data and the severity of symptoms— pain, venous redness, and venous edema—were assessed on a 0–10 scale. Symptoms were classified as mild (1–3), moderate (4–7), or severe (8–10). After 14 days, symptom severity was reassessed. Results: Pain was the most severe symptom initially (mean 4.65, SD = 2.38), with redness (mean 3.90, SD = 2.13) and edema (mean 3.74, SD = 1.99) also prominent. Significant improvements were noted after treatment: pain intensity decreased to a mean of 1.71 (SD = 1.31, improvement in 95.7% of patients), redness to 1.52 (SD = 1.11, 88.4% improvement), and edema to 1.43 (SD = 0.99, 92.8% improvement). Patients valued immediate relief (cooling sensation), efficacy, non-staining properties, pleasant smell, quick absorption, and the gel’s light formulation, with 86% appreciating the high heparin dose. Conclusions: This study suggests that topical heparin gel (2400 IU/g) offers an effective treatment option for SVT, with patient-preferred properties enhancing its clinical attractiveness.